Are you Dr. Schwarz?
Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.
- Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
You already have 73 invites waiting! - Read the latest clinical news, personalized to your specialty.
Office
988102 Nebraska Medical Ctr
Omaha, NE 68198Phone+1 402-559-4015
Summary
- Dr. James Schwarz, MD is an oncologist in Omaha, Nebraska. He is currently licensed to practice medicine in Nebraska, New York, and Missouri. He is affiliated with Nebraska Medicine - Nebraska Medical Center, Nebraska Medicine - Bellevue, and Memorial Community Hospital and Health System.
Education & Training
University of Missouri-ColumbiaFellowship, Hematology and Medical Oncology, 1998 - 2001
Duke University HospitalFellowship, Infectious Disease, 1990 - 1994- Duke University HospitalResidency, Internal Medicine, 1987 - 1990
Duke University School of MedicineClass of 1987
Certifications & Licensure
NE State Medical License 2008 - 2026
MO State Medical License 1998 - 2021
NY State Medical License 2001 - 2008
NC State Medical License 1989 - 1995- American Board of Internal Medicine Hematology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2013
Clinical Trials
- Sorafenib Tosylate With or Without Doxorubicin Hydrochloride in Treating Patients With Locally Advanced or Metastatic Liver Cancer Start of enrollment: 2010 Feb 15
- A Study of Ramucirumab (LY3009806) Plus Docetaxel in Participants With Urothelial Cancer Start of enrollment: 2015 Jul 13
Publications & Presentations
PubMed
- 21 citationsPhase I trial of concurrent stereotactic body radiotherapy and nelfinavir for locally advanced borderline or unresectable pancreatic adenocarcinomaChi Lin, Vivek Verma, Quan P. Ly, Audrey J. Lazenby, Aaron R. Sasson
Radiotherapy and Oncology. 2019-03-01 - 40 citationsCabozantinib Versus Mitoxantrone-prednisone in Symptomatic Metastatic Castration-resistant Prostate Cancer: A Randomized Phase 3 Trial with a Primary Pain EndpointEthan Basch, Mark C. Scholz, Johann S. de Bono, Nicholas J. Vogelzang, Paul de Souza
European Urology. 2019-06-01 - 52 citationsRamucirumab plus docetaxel versus placebo plus docetaxel in patients with locally advanced or metastatic urothelial carcinoma after platinum-based therapy (RANGE): ove...Daniel P. Petrylak, Ronald de Wit, Kim N. Chi, Alexandra Drakaki, Cora N. Sternberg
The Lancet. Oncology. 2020-01-01
